Data-Driven Medicine Award Archives

🏛️Early Academic Pursuits

Zongzhi Liu’s academic journey is deeply rooted in the exploration of human diseases and immunotherapy. His early academic work laid the foundation for his current focus on the mechanisms of neurodegenerative diseases and tumor immunotherapy. By leveraging next-generation sequencing and bioinformatics, he has significantly contributed to the understanding of disease pathways and therapeutic targets.

Liu’s professional endeavors are characterized by his commitment to precision medicine and epigenetic research. His notable projects include the development of epigenetic biomarkers for early cancer diagnosis and targeted therapy. His work with Runx3 knockout mouse models has provided critical insights into the epigenetic regulation of PD-1 tumor treatment response and resistance.

Liu utilized the SCADEN algorithm to predict primary pathways involved in neuron degeneration, specifically focusing on Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Amyotrophic Lateral Sclerosis (ALS). His research integrates behavioral experiments in mice to explore these mechanisms further.

Through multi-omics analysis, Liu identified epigenetic targets for tumor immunotherapy. His establishment of a Runx3 knockout mouse model was pivotal in demonstrating that Runx3 epigenetic reprogramming is a key regulator of PD-1 tumor treatment response and resistance.

Liu’s innovations extend to several high-impact projects:
- Molecular Mechanism of T Cell Function: Studied the regulation of T cell function related to RUNX3 methylation reprogramming, funded by the National Natural Science Foundation (2023-2025).
- Emerging Infectious Diseases: Contributed to pathogen identification and early warning technology for infectious diseases, as part of a national task (2021-2024).
- Combined Immunotherapy: Investigated the synergistic effects of combined immunotherapy, with significant clinical implications (2016-2022).
- Maternal Age and Pregnancy Outcomes: Explored the impact of advanced maternal age on pregnancy outcomes and offspring health (2018-2022).
- Liquid Biopsy Technology: Evaluated liquid biopsy technology for early cancer screening and diagnosis (2019-2021).

National Natural Science Foundation Project: Molecular mechanism study on T cell function regulation (2023-2025).
National Task Project: Study on pathogen identification and early warning technology (2021-2024).
National Key R&D Program: Research on combined immunotherapy (2016-2022).
National Natural Science Foundation Key Project: Impact of advanced maternal age on pregnancy outcomes (2018-2022).
Ministry of Science and Technology Key R&D Program: Liquid biopsy technology for early cancer diagnosis (2019-2021).

Liu’s research has significantly impacted the fields of neurodegenerative diseases and tumor immunotherapy. His work on epigenetic reprogramming and precision medicine has paved the way for innovative approaches to early diagnosis and targeted therapy, influencing both clinical practices and future research directions.

Zongzhi Liu holds esteemed editorial appointments as a reviewer for Frontiers in Oncology and Frontiers in Pediatrics, contributing his expertise to the peer-review process. His collaborative efforts span multiple prestigious institutions, including the General Hospital of the People’s Liberation Army of China, the Institute of Pathogen Biology at the Chinese Academy of Medical Sciences, Peking University Third Hospital, and the Cancer Hospital of the Chinese Academy of Medical Sciences. As a member of the Chinese Society for Cell Biology, Liu actively participates in advancing the field of bioinformatics in human diseases. His research focuses on bioinformatics, with a particular interest in the mechanisms of neurodegenerative diseases and tumor immunotherapy, underscoring his commitment to the intersection of epigenetics and precision medicine.

Liu’s legacy in the scientific community is marked by his groundbreaking research and dedication to advancing medical science. His future contributions are anticipated to further enhance our understanding of disease mechanisms and therapeutic strategies, ultimately improving patient outcomes and shaping the future of precision medicine.

Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy
- Authors: Liu, Z., Li, X., Gao, Y., Mei, Q., Sun, Y.
- Journal: Molecular Cancer, 2023, 22(1), 84
CRISPR-Cas13d effectively targets SARS-CoV-2 variants, including Delta and Omicron, and inhibits viral infection
- Authors: Liu, Z., Gao, X., Kan, C., Zhang, Z., Sun, Y.
- Journal: MedComm, 2023, 4(1), e208
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
- Authors: Jing, C., Wang, J., Zhu, M., Zhang, Z., Deng, W.
- Journal: Cancer Immunology, Immunotherapy, 2022, 71(11), pp. 2597–2608
Whole-genome circulating tumor DNA methylation landscape reveals sensitive biomarkers of breast cancer
- Authors: Hai, L., Li, L., Liu, Z., Tong, Z., Sun, Y.
- Journal: MedComm, 2022, 3(3), e134
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
- Authors: Wang, Y., Tong, C., Dai, H., Zhang, Y., Han, W.
- Journal: Nature Communications, 2021, 12(1), 409